Cargando…

LGG-14. TREATMENT OF TWO PEDIATRIC FGFR-ALTERED LOW-GRADE GLIONEURONAL TUMORS WITH MEK INHIBITION

Somatic alterations in the fibroblast growth factor receptor (FGFR) gene family (FGFR1/2/3) have been implicated in tumorigenesis across pediatric low-grade glioneuronal neoplasms and represent a potential therapeutic target. FGFR rearrangements and internal tandem duplication (ITD) cause constituti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lazow, Margot, Thomas, Diana, Cottrell, Catherine, Kobolt, Daniel, Ramadesikan, Swetha, Salloum, Ralph, Shaikhouni, Ammar, Mardis, Elaine, Jones, Jeremy, Leonard, Jeffrey, Boué, Daniel, Fouladi, Maryam, Schieffer, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Low Grade Gliomas - LGG
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259957/ http://dx.doi.org/10.1093/neuonc/noad073.224

Ejemplares similares

LGG-24. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR MANAGEMENT AND OUTCOME: A SINGLE CENTER EXPERIENCE
por: Munir, Faryal, et al.
Publicado: (2023)

LGG-20. LANDSCAPE OF FGFR ALTERATIONS IN PEDIATRIC AND AYA GLIOMAS
por: Nobre, Liana, et al.
Publicado: (2023)

LGG-21. FGFR1 GENE MUTATION AS A POTENTIAL RISK FACTOR FOR SPONTANEOUS INTRACRANIAL HEMORRHAGE IN PEDIATRIC LOW GRADE GLIOMA PATIENTS
por: Lebert, Brittany, et al.
Publicado: (2023)

LGG-03. EXPLORING THE SIGNALING NETWORK INVOLVED IN MAPK PATHWAY INHIBITION BY THE MEK INHIBITOR TRAMETINIB IN BRAF-FUSION-DRIVEN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-22. CHARACTERIZATION OF THE TUMOR MICROENVIRONMENT IN PEDIATRIC LOW-GRADE GLIOMA
por: Zahedi, Shadi, et al.
Publicado: (2023)

LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
por: Levine, Adrian, et al.
Publicado: (2023)

LGG-10. TREATMENT-RELATED MYELODYSPLASTIC SYNDROME FOLLOWING CHEMOTHERAPY FOR PEDIATRIC LOW-GRADE GLIOMA
por: Power, Phoebe, et al.
Publicado: (2023)

LGG-17. EPIGENETICALLY DEFINED ANGIOCENTRIC GLIOMAS MAY LACK ANGIOCENTRIC GROWTH AND INSTEAD SHOW A VARIETY OF GROWTH PATTERNS
por: Stegat, Lotte, et al.
Publicado: (2023)

LGG-19. MULTI-MODALITY CHARACTERIZATION OF PEDIATRIC LOW-GRADE GLIOMA: THE ADDED VALUE OF DIFFERENT DATA MODALITIES
por: Haldar, Debanjan, et al.
Publicado: (2023)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

LGG-04. CLINICALLY RELEVANT MODELING OF FUSION-DRIVEN PEDIATRIC LOW GRADE GLIOMAS USING DROSOPHILA MELANOGASTER
por: Jung, Geena, et al.
Publicado: (2023)

LGG-05. IMAGING-BASED DEEP LEARNING FOR EVENT-FREE SURVIVAL PREDICTION IN PATIENTS WITH PEDIATRIC LOW-GRADE GLIOMA
por: Zapaishchykova, Anna, et al.
Publicado: (2023)

LGG-13. GANGLIOGLIOMA DEEP TRANSCRIPTOMICS REVEALS A CD34+ PRIMITIVE NEUROECTODERM NEURAL PRECURSOR-LIKE POPULATION
por: Regal, Joshua, et al.
Publicado: (2023)

LGG-07. TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS; REAL WORLD DATA IN THE CONTEXT OF CONVENTIONAL TREATMENT MODALITIES
por: Sumerauer, David, et al.
Publicado: (2023)

LGG-30. TRAMETINIB-ASSOCIATED HYPONATREMIA IN A CHILD WITH LOW GRADE GLIOMA IS NOT SEEN FOLLOWING TREATMENT WITH ALTERNATIVE MEK INHIBITOR
por: Lazow, Margot A, et al.
Publicado: (2020)

LGG-09. CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
por: Kilburn, Lindsay, et al.
Publicado: (2023)

LGG-23. OUTCOMES UTILIZING BRAF INHIBITION MONOTHERAPY IN BRAF(V600E) MUTATED PEDIATRIC LOW GRADE GLIOMAS
por: McThenia, Sheila, et al.
Publicado: (2023)

LGG-11. COGNITIVE, ACADEMIC, AND QUALITY OF LIFE OUTCOMES IN SURVIVORS OF PEDIATRIC LOW-GRADE GLIOMA: CHALLENGING THE ‘BENIGN TUMOR’ PERCEPTION
por: Nagabushan, Sumanth, et al.
Publicado: (2023)

LGG-15. SINGLE-NUCLEUS AND BULK RNA SEQUENCING OF PEDIATRIC PILOCYTIC ASTROCYTOMAS REVEALS CNS LOCATION-ASSOCIATED TUMOR CELL AND MICROENVIRONMENTAL HETEROGENEITY
por: Lammers, Julie A S, et al.
Publicado: (2023)

LGG-08. TARGETED THERAPY IN BRAF(V600E)-DRIVEN PEDIATRIC GLIOMAS: UNCOVERING MECHANISMS OF RESISTANCE THROUGH A MULTI-OMIC APPROACH
por: Capogiri, Monica, et al.
Publicado: (2023)

LGG-01. DEVELOPMENT OF A WEB-BASED CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERMSURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
por: Brown, Nolan, et al.
Publicado: (2023)

LGG-02. DRUG-CLASS SPECIFIC GENE-BASED MAPK SENSITIVITY SCORES (MSS) PREDICT SENSITIVITY TO MAPK INHIBITORS AND IDENTIFY IMMUNE INFILTRATION AS PUTATIVE TARGET IN PEDIATRIC LOW-GRADE GLIOMAS
por: Sigaud, Romain, et al.
Publicado: (2023)

LGG-06. DEVELOPMENT OF A WEB-BASED MOBILE DEVICE CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERM SURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
por: Brown, Nolan, et al.
Publicado: (2023)

LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES
por: Valiakhmetova, Andge, et al.
Publicado: (2020)

LGG-47. SYSTEMIC THERAPY OF ROSETTE-FORMING GLIONEURONAL TUMOR OF THE FOURTH VENTRICLE INAN ADOLESCENT
por: McNall-Knapp, Rene, et al.
Publicado: (2020)

LGG-31. CHARACTERIZING TEMPORAL GENOMIC HETEROGENEITY IN PEDIATRIC LOW GRADE GLIOMAS: ANALYSIS OF AN EXPANDED MULTI-INSTITUTIONAL COHORT WITH 101 PAIRED TUMOR SAMPLES
por: Lazow, Margot A, et al.
Publicado: (2020)

LGG-31. Pediatric low-grade gliomas with FGFR1 mutations and spontaneous hemorrhage: case series
por: Campion, Stephani, et al.
Publicado: (2022)

LGG-02. Cardiac toxicity in patients receiving single-agent MEK inhibition
por: Cantor, Evan, et al.
Publicado: (2022)

LGG-48. The influence of different FGFR1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response
por: Morin, Eric, et al.
Publicado: (2022)

LGG-04. A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (pLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Fangusaro, Jason, et al.
Publicado: (2020)

LGG-62. Weight change in pediatric patients treated with MEK inhibitors: a retrospective cohort study
por: Hyun Bahng, Hye, et al.
Publicado: (2022)

LGG-63 MEK inhibitor-associated retinopathy (MEKAR) in a pediatric patient with an optic pathway glioma
por: Bendel, Anne, et al.
Publicado: (2022)

LGG-17. CLINICAL OUTCOME OF PEDIATRIC LOW GRADE GLIOMA WITH POSITIVE BRAF-FUSION TREATED WITH MEK INHIBITOR
por: Dennis, T L Ku, et al.
Publicado: (2021)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-11. INSTITUTIONAL EXPERIENCE OF BRAF TARGETING THERAPY
por: Lola, Gino Bardi, et al.
Publicado: (2020)

LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG)
por: Vinitsky, Anna, et al.
Publicado: (2022)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-27. Molecular implications of mitogen-activated protein kinase pathway inhibition by the MEK inhibitor trametinib in BRAF-fusion-driven pediatric pilocytic astrocytoma
por: Sigaud, Romain, et al.
Publicado: (2022)

LGG-23. Cardiac function in children and young adults treated with MEK inhibitors: a single institution retrospecive cohort study
por: Robison, Nathan, et al.
Publicado: (2022)

LGG-38. Dose-dependent seizure control for an NF1 patient treated via MEK-inhibition for optic pathway glioma
por: Cantor, Evan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t9i4nm5cd15814sclge3npgmnf